Alsaqaaby Moath S, le Roux Carel W
Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin, Ireland.
Obesity, Endocrine and Metabolism Center, King Fahad Medical City, Riyadh, Saudi Arabia.
Diabetol Int. 2023 Apr 4;14(3):217-223. doi: 10.1007/s13340-023-00626-0. eCollection 2023 Jul.
Obesity is now recognised as a disease associated with significant morbidity and mortality. One of the most common metabolic complications of obesity is type 2 diabetes, because the two disease share similar pathophysiology. Weight loss is known to ameliorate the metabolic abnormalities underlying type 2 diabetes and improve glycemic control. A 15% or greater total body weight loss (TBWL) in patients with type 2 diabetes will have a disease-modifying effect, a result that is incomparable with other hypoglycemic-lowering interventions. Moreover, in patients with diabetes and obesity, weight loss exerts benefits beyond glycemic control and improves cardiometabolic disease risk factors and well-being. We review evidence supporting the role of intentional weight loss in managing type 2 diabetes. We suggest that many people with type 2 diabetes would benefit from an additional weight-based approach to managing their diabetes. Therefore, we proposed a weight-based treatment goal for patients with type 2 diabetes and obesity.
肥胖现在被认为是一种与显著发病率和死亡率相关的疾病。肥胖最常见的代谢并发症之一是2型糖尿病，因为这两种疾病具有相似的病理生理学。众所周知，体重减轻可改善2型糖尿病潜在的代谢异常并改善血糖控制。2型糖尿病患者总体重减轻（TBWL）15%或更多将具有疾病改善作用，这一结果与其他降糖干预措施不可比拟。此外，在糖尿病和肥胖患者中，体重减轻带来的益处不仅限于血糖控制，还可改善心脏代谢疾病风险因素并提高幸福感。我们综述了支持有意减肥在管理2型糖尿病中作用的证据。我们认为，许多2型糖尿病患者将从额外的基于体重的糖尿病管理方法中受益。因此，我们为2型糖尿病和肥胖患者提出了基于体重的治疗目标。
